和元生物: 关于完成董事会换届选举及聘任高级管理人员的公告

Group 1 - The company held its second extraordinary general meeting of shareholders on June 27, 2025, to elect the fourth board of directors, including non-independent and independent directors, along with employee representative directors [1][2] - The newly elected board consists of four non-independent directors and four independent directors, along with one employee representative director, with a term of three years starting from the approval date of the meeting [2][3] Group 2 - The first meeting of the fourth board of directors was held on June 27, 2025, where several key resolutions were passed, including the election of the chairman and the establishment of various specialized committees [2][4] - Mr. Pan Oudong was elected as the chairman of the fourth board, and various committees such as the Strategy and ESG Committee, Audit Committee, Compensation and Assessment Committee, and Nomination Committee were formed with specific members [3][4] Group 3 - The company appointed Mr. Pan Oudong as the general manager and several other individuals as vice general managers and financial officers, with their terms aligned with the board's term [5][6] - The newly appointed senior management team includes individuals with relevant qualifications and experience, ensuring compliance with legal and regulatory requirements [6][9] Group 4 - The company has decided to abolish the supervisory board, transferring its powers to the audit committee of the board, and the relevant rules have been updated accordingly [7] - The previous supervisory board members have completed their terms and will no longer serve in their roles, with acknowledgments for their contributions during their tenure [7][8]